Share

Contacts

  • Quotes

    This financing can cover the company’s capital requirements to product registration following a positive outcome in the European phase 3 study. It can also secure financing for an additional study if needed before registration. We are continuing our focus on MOB-015 and look forward to the topline data from the EU study at the end of the second quarter. We are fully committed to creating the future market leader in nail fungus treatments
    Anna Ljung, CEO of Moberg Pharma
    The agreement provides Moberg Pharma access to flexible financing at a reasonable cost under current market conditions. As part of the agreement, Nice & Green will introduce Moberg Pharma to its wide network of biotech investors in Switzerland, Germany and France
    Mark Beveridge, VP Finance at Moberg Pharma
    The high mycological cure rate demonstrated is very impressive and given the rapid onset of the antifungal effect, MOB-015 offers exciting benefits. I will definitely use it for my patients. A higher complete cure rate is likely to be achieved with a shorter treatment period and this would also be much more attractive to patients
    Dr Boni Elewski, Professor and Chair of the Department of Dermatology, University of Alabama.
    I am a strong supporter of this concept. With an optimized dosing regimen this product has great potential and may become the preferred therapeutic option, not only for monotherapy, but also as maintenance therapy to reduce recurrence after oral treatment
    Dr Aditya Gupta, Professor, Department of Medicine, University of Toronto
    Based on decades of experience with terbinafine and the excipients used in MOB-015, I believe a shorter treatment period has the potential to provide higher complete cure rates. Killing the fungus is the driver of also reaching complete cure
    Dr Jan Faergemann, Professor in Dermatology, Sahlgrenska Academy, University of Gothenburg, Sweden.
    From a medical and commercial perspective, a regimen with daily dosing for up to three months followed by less frequent treatment, is highly attractive and further improves the target product profile of MOB-015. This is further supported by U.S. market data indicating that real-life usage of current topicals on average is 3-4 months, despite being labeled for 48 weeks’ daily treatment
    Dr. Amir Tavakkol, CSO of Moberg Pharma AB
    We are very grateful for the thorough analysis of the key opinion leaders which not only shed light on the conflicting data points, but also strengthened our conviction that MOB-015 has the potential to become the future market leader in onychomycosis
    Anna Ljung, CEO of Moberg Pharma AB.
    The mycological cure rate in the study is remarkably high for a topical treatment. We believe this is due to fungicidal activity of terbinafine in MOB-015. We would normally expect more patients reaching complete cure following eradication of the infection in such a clear majority of the patients. This will be further investigated and we expect additional insights from the European study (n=452), in which MOB-015 is compared head to head against the most widely used topical treatment. A safe, efficacious topical terbinafine product eradicating the infection and progressing healthy nail growth for many patients is highly attractive for practicing physicians worldwide
    Amir Tavakkol, Senior Advisor R&D at Moberg Pharma AB.
    To cure 70 percent of the patients from their fungal nail infection is a superior result and better than expected for a topical product. We were however expecting a higher complete cure rate, following the high mycological cure, despite the well-known challenges in demonstrating completely cleared nails at 52 weeks even after the fungal infection is cured. The study confirms the rapid visible improvement experienced by patients, where four out of five patients reported some improvement already at the first follow up visit, and at the end of the study, 33 percent of patients rated their nail to be cured or almost cured
    Anna Ljung, CEO of Moberg Pharma AB
    This is the fourth commercial agreement for MOB-015, this time with the market leader in dermatology in Korea with excellent coverage of the dermatology clinics. We look forward to work with DongKoo and making MOB-015 available in Korea, contributing to our vision of making MOB-015 the leading nail fungus treatment worldwide
    Anna Ljung, CEO of Moberg Pharma
    I look forward to continue working together with Mark Beveridge. I would also like to thank Sarah Hellerfelt for her excellent contributions to the company over the past years and wish her all the best in the future
    Anna Ljung, CEO of Moberg Pharma
    We are excited to partner with Taisho for the large and growing Japanese onychomycosis market, contributing to our vision of making MOB-015 the leading nail fungus treatment worldwide
    Anna Ljung, CEO of Moberg Pharma
    This is the third major agreement for MOB-015 and further validates the significant market potential for our lead asset and the focused commercialization preparations by our team
    Peter Wolpert, Executive Chairman of Moberg Pharma
    After the successful divestment of the OTC portfolio, the business is progressing as planned with a focus on the Phase 3 studies for MOB-015, further commercialization preparations and preparations for the share redemption in November 2019
    Anna Ljung, CEO of Moberg Pharma
    The divestment of our OTC business represents a major change for Moberg Pharma and recognize the compelling value of both components of the business. Since April 1, 2019, Moberg Pharma has a fully funded business whose main goal is to make MOB-015 the future market leader in onychomycosis
    Peter Wolpert, VD Moberg Pharma
    I look forward to the opportunity to transition to a role as Executive Chairman while remaining close to the new management. After 13 intensive years as CEO of Moberg Pharma, it is important for me to be able to spend more time with my family, as well as continuing to contribute in a valuable way according to the company’s new needs
    Peter Wolpert, CEO of Moberg Pharma AB
    We are excited about this opportunity – being able to offer our shareholders a significant distribution while retaining the considerable upside of the fully funded MOB-015 program. The transaction enables us to increase the focus on making MOB-015 the future market leader in onychomycosis. I would also like to thank the OTC team for their exceptional contributions to Moberg Pharma over the past years and wish them continued success
    Peter Wolpert, Moberg Pharma´s CEO
    Completing the Phase 3 enrollment for MOB-015 is truly an important milestone. I am very grateful to the team for the hard work in completing the recruitment for both studies. More than 5,000 patients have been screened to recruit 800+ patients in the rigorous screening process, ultimately increasing the probability of strong phase 3 results for MOB-015
    Peter Wolpert, Moberg Pharma’s CEO
    As we conclude 2018, we’re pleased to report that EBITDA exceeded 100 MSEK for the first time. For MOB-015, patient screening for the European Phase 3 study was recently completed along with a second major license agreement, for Europe. The strong progress enabled today’s major event which realizes a premium value for our OTC business while indicating the significant value of MOB-015
    Peter Wolpert, CEO of Moberg Pharma
    We are excited to announce this transformational transaction. The transaction delivers exceptional value for the OTC-business and further validates the significant potential in MOB-015. The proceeds from this transaction offer near-term liquidity to our shareholders while preserving future upside. I would like to commend and thank our team for all of their hard work. Over the last few years we have acquired, built and generated superior performance for the company, and those efforts are reflected in this transaction
    Peter Wolpert, CEO Moberg Pharma
    After a thorough process, the board is convinced that the proposed transaction is the most attractive and brings significant value to the shareholders. The combination of a premium consideration for the OTC-business, specialized U.S. Healthcare investors entering at a premium valuation, while repaying outstanding debt, is highly attractive. Shareholders benefit from receiving a significant dividend while retaining the considerable upside of the MOB-015 program
    Thomas Eklund, Chairman of the board at Moberg Pharma
    We are thrilled to partner with Bayer for the European launch, as part of our vision of making MOB-015 the leading nail fungus treatment worldwide. This is the second major agreement for MOB-015 and a further validation of the significant market potential for our asset
    Peter Wolpert, Moberg Pharma’s CEO
    We are excited about the opportunity to partner with Moberg and the potential to bring this cutting-edge technology to market in order to advance one of our key categories
    Heiko Petersen, Head of Bayer’s Global Category Business Unit Dermatology
    It is a great pleasure to welcome Annica Magnusson and Gunilla Wengström to the Management Team at Moberg Pharma. Both Annica and Gunilla have assumed increasing senior responsibilities over the last year and I look forward to working together with them to continue to deliver on our strategy
    Peter Wolpert, CEO of Moberg Pharma AB
    Having been granted the Chinese patent means we now cover the main markets in which we are planning to commercialize MOB-015. It is an important milestone in our strategy to establish a broad patent protection for our proprietary products
    Peter Wolpert, Moberg Pharma´s CEO
    I’m very pleased with the continued momentum in our commercial operations as well as the progress for MOB-015 where we completed the enrollment for the North American phase 3-study and signed the first license agreement, confirming the market potential for our lead pipeline asset
    Peter Wolpert, CEO of Moberg Pharma
    We look forward to developing our relationship with Mundipharma and making Emtrix® available in new regions as we expand our footprint in growing markets
    Peter Wolpert, Moberg Pharma´s CEO
    This newly signed agreement with Moberg Pharma will give onychomycosis patients in MEA region access to one of the leading treatments for this common and uncomfortable nail fungal condition
    Dr. Ashraf Allam, Vice President of Mundipharma META
    The license agreement with Cipher Pharmaceuticals is a key step in preparing the global launch of MOB-015 and it confirms the significant market potential for our product. Cipher has excellent capabilities to make MOB-015 a success in Canada. We look forward to this exciting partnership and continue to progress commercialization plans in other key markets as we approach Phase 3 results
    Peter Wolpert, Moberg Pharma´s CEO
    We are excited at the prospect of bringing an innovative topical product to market that would be a provide a new safe and effective treatment option for the many Canadians who suffer from onychomycosis. The addition of MOB-015 represents our sixth transaction of the year and demonstrates the continued execution of our growth strategy as we build a pipeline of diversified and differentiated near term products for the Canadian market
    Robert Tessarolo, President and CEO of Cipher
    Completing the enrollment in North America is an important milestone and the result of excellent work from the team. I am very pleased with the progress and the rigorous screening process which increases the probability of strong phase 3 results
    Peter Wolpert, Moberg Pharma’s CEO
    We look forward to welcoming Shaw to Moberg Pharma. He will be joining the company in a highly exciting stage as we approach phase 3-results for MOB-015, where he will be adding valuable experience from the development, launch and commercialization of novel treatments
    Peter Wolpert, CEO Moberg Pharma
    Net revenue for the three key brands in the U.S. grew at record pace, fundamentally outpacing the market and strengthening our leading position in all key categories, while significantly increasing profitability. Meanwhile, MOB-015 studies are progressing according to plan with screening in North America recently completed
    Peter Wolpert, CEO of Moberg Pharma
    Over the past years, Mark Beveridge has played a key role in Moberg Pharma’s finance and transaction teams. It’s a pleasure to welcome Mark to the management team and I look forward to working together with him to continue developing Moberg Pharma’s operations
    Peter Wolpert, CEO of Moberg Pharma
    The year has begun with strong profitability and significant growth for all our key brands and the Phase 3 studies for MOB015 are progressing according to the November 2017 plan. For the first quarter, the company generated revenue growth of 5% adjusted for divested brands, despite currency headwind. In local currency, net revenue for our key brands grew by 12-17%. The EBITDA margin improved from 16% to 24%
    Peter Wolpert, CEO of Moberg Pharma
    This issuance of this patent in the United States is part of our overall strategy to establish a broad portfolio of patent claims to protect our proprietary products and is an important milestone, as we now have granted patents in all territories where we have applied for patent protection.
    Peter Wolpert, Moberg Pharma’s CEO
    With extensive knowledge and experience, Kjell has contributed to the evolution of Moberg Pharma, especially through the development of Kerasal Nail® and MOB-015, where he has been instrumental. I’ve had the pleasure of working with Kjell since 2007 and I am highly grateful for his efforts over the years. I look forward to continuing our collaboration in his role as Senior Advisor to the company
    Peter Wolpert, CEO Moberg Pharma
    We are pleased with the divestment. We have now successfully divested most of our minor brands, enabling us to focus our resources on growing our larger brands
    Peter Wolpert, CEO Moberg Pharma
    Successful marketing and integration of acquisitions has resulted in double-digit growth in retail sales for our three major brands
    Peter Wolpert, CEO of Moberg Pharma
    We are highly pleased with the outcome from NAD and we expect the outcome to further strengthen Kerasal Nails® position and growth prospects in the U.S. market
    Peter Wolpert, CEO of Moberg Pharma AB
    The new organization better reflects the company’s increased focus on the North American market and to progress toward the commercialization of MOB-015, while also enabling synergies in the global sales operations. I would like to thank Martin Ingman for the important work he has done for the company and wish him all the best in the future
    Peter Wolpert, CEO of Moberg Pharma AB
    Replacing the CRO is a key step in the extensive action program that was recently announced. TFS has the capability to accelerate patient recruitment and finalizing the European study. Combined with the new setup in North America, we are confident in achieving strong Phase 3 results within the timeline
    Peter Wolpert, Moberg Pharma’s CEO
    MOB-015 is our most valuable pipeline asset and we see a potential to meet the significant unmet needs of patients suffering from nail fungus. The team is working hard to balance a rigorous screening process while maintaining an aggressive timeline for completing the enrollment. The rigorous screening process is instrumental for the outcome of the Phase 3 studies and to achieve strong claims
    Peter Wolpert, Moberg Pharma’s CEO
    It is a pleasure to welcome Torbjörn to the Management Team at Moberg. I look forward to working together to continue driving the growth of our development programs
    Peter Wolpert, CEO of Moberg Pharma AB
    This issuance of this patent is an important part of our overall strategy to establish a broad portfolio of patent claims to protect our proprietary products
    Peter Wolpert, Moberg Pharma’s CEO
    We are pleased with the agreement with Caret Pharma LLC. which enables us to increase focus on the core Moberg Pharma portfolio. We have now successfully divested both non-core brands included in the acquisition from Prestige Brands, while the acquired strategic brands are developing well
    Peter Wolpert, CEO Moberg Pharma
    Kerasal Nail® reached a market share of 29%, while at the same time, we have expanded distribution for both Dermoplast® and New Skin®. Enrolment for the MOB-015 study has taken longer than expected but is accelerating after corrective measures have been implemented
    Peter Wolpert, CEO Moberg Pharma
    The successful results from patients with nail psoriasis, and for the study as a whole, make a stronger selling point for Kerasal Nail®/ Emtrix®, something which is of great importance for future efforts in all markets
    Peter Wolpert, CEO of Moberg Pharma
    This is our most recent acquisition and we are pleased that the integration is progressing according to plan. The distribution gains provide excellent opportunities to build on the brand equity of Dermoplast® in the years to come
    Jeff Vernimb, GM of Moberg Pharma North America
    We are excited about the prospects for Zanmira Nail® in Japan, which has the potential to become a major market for Moberg Pharma. We look forward to the continued collaboration with CMIC in Japan, as well as with Menarini in the other markets of the Asia-Pacific region
    Peter Wolpert, CEO of Moberg Pharma
    Pick a time period -
    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media